Analytical Method Development and Validation for Estimation of Mifepristone in Pure and Pharmaceutical Dosage Form

Sheetal Bastia a, Vaibhav Gawade b*, Vitthal Chopade c, Rahul Jagtap b and Vishal Modi d

a Department of Pharmaceutical Quality Assurance, SSR College of Pharmacy, Affiliated to Savitribai Phule Pune University, Silvassa, D&NH-396230, India.
b Department of Pharmaceutical Chemistry, Dr. D.Y. Patil Institute of Pharmaceutical Sciences and Research, Pimpri, Pune-411018, India.
c Department of Pharmaceutical Chemistry, PES Modern college of pharmacy, Yamuna Nagar Nigdi, Pune-44, India.
d Department of Pharmaceutical Chemistry, SSR College of Pharmacy, Affiliated to Savitribai Phule Pune University, Silvassa, D&NH-396230, India.

Authors’ contributions

This work was carried out in collaboration among all authors. All authors read and approved the final manuscript.

Article Information

DOI: 10.9734/JPRI/2021/v33i60B34594

Open Peer Review History:

This journal follows the Advanced Open Peer Review policy. Identity of the Reviewers, Editor(s) and additional Reviewers, peer review comments, different versions of the manuscript, comments of the editors, etc are available here: https://www.sdiarticle5.com/review-history/79719

Received 15 October 2021
Accepted 19 December 2021
Published 21 December 2021

ABSTRACT

Mifepristone structurally belongs to the class of anti-progesterone steroids, which are used as an oral contraceptive. The reverse phase HPLC method was designed in a simplified and rapid way for the estimation of Mifepristone in bulk as well as tablets. The method was established using a Kromasil C_{18} column of dimensions of 250mm×4.6mm and a particle size of 5m. The used mobile phase was Acetonitrile: Water (70:30, v/v). The pump was pumped at 1 ml/min at a temperature of about 30 ± 2 °C and the eluted analyte was identified at 305 nm. Mifepristone eluted with a mean retention time of 6.27 minutes. The intended method was validated as per ICH (International Council for Harmonisation) guidelines, indicating a high degree of specificity, system suitability, accuracy, precision, and robustness. The LOD (Limit of detection) was found to be 0.7238 ppm and the limit of measurement was 0.9562 ppm. The method linearity was found to be between 1-6μg/ml, with an R^2 of 0.9923. In accuracy studies, the percent recovery was found to be between 99.39% - 100.50%. The method was discovered to be precise as the values of the percent RSD

*Corresponding author: E-mail: gawadevaibhav6060@gmail.com;
were found to be less than 2.0% for both intraday and interday. The method was discovered to be reliable and robust. Mifepristone in marketed pharmaceutical tablet dosage form was effectively quantified using the established Reverse Phase HPLC method.

Keywords: Limit of detection; anti-progesterone; reverse phase; robustness; ICH guideline.

**ABBREVIATIONS**

MIF: Mifepristone
ACETONITRILE: Acetonitrile,
ICH: International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use

**1. INTRODUCTION**

Unintended pregnancies are those that are unplanned or unwanted during conception. It is one of the most troubling public health complications and a severe reproductive health issue, which includes accidental pregnancy [1]. The World Health Organization (WHO) states that approximately 70,000 maternal deaths are due to the complications of unintended pregnancy, which further results in legal unsafe abortion, and that about 585,000 women die each year due to the complications of unintended pregnancy that result in child birth [2]. Mifepristone is a 19-nor steroid with an effective and competitive antagonist of glucocorticoids and progesterone to give anti-progesterone activity [3]. It has major special effects on ovulation [4]. If given precisely in between the follicular phases, it leads to delayed follicular maturation and ovulation as compared to normal. If this drug is given continuously, then ovulation is prevented [5]. It inhibits the growth of secretory endometrium, which leads to the production of menstruation [6]. Mifepristone has anti-glucocorticoid and anti-androgenic properties when combined with glucocorticoid and androgen receptors [7-9]. The use of mifepristone in the first trimester of pregnancy further leads to abortion. It is also used as a post-coital contraceptive [8-11]. The mechanism of action of Mifepristone is presented in:

![Fig. 1. Mechanism of mifepristone](image1)

![Fig. 2. Structure of mifepristone](image2)
An exhaustive search reveals that no analytical techniques like UV, HPLC, and stability indicating methods for the determination of Mifepristone as an individual have been reported [12-14]. There was no method reported to quantify Mifepristone by HPLC. However, a fresh method has been created for estimating Mifepristone that is accurate, specific, precise, and repeatable [14-16].

2 EXPERIMENTAL

2.1 Methods

A standard drug of Mifepristone (purity of 99% w/w) was obtained. Both HPLC grade Methanol and HPLC grade Water were purchased in Mumbai, India by Fisher Scientific India Pvt. Ltd. and Rankem, Haryana, India. Termipil kit tablets manufactured by Alkem Labs contain 200 mg of Mifepristone as per label claim and were acquired from a pharmacy shop.

2.2 Chromatographic Conditions and HPLC Instrumentation

HPLC studies were carried out using the Jasco HPLC system 4000 series, consisting of a quaternary pump (PU-4180-LPG), a degasser, an auto-sampler (AS-4050) and a UV detector. All the chromatograms obtained were evaluated using Chrom-NAV version 2.0 software. The used mobile phase was Acetonitrile: Water (70:30, v/v). Flow rate of 1 ml/min, which was fine-tuned by trial and error. At a distance of 305 mm, detection was made.

3 METHODS

3.1 Preparation of Solutions

3.1.1 Standard stock solution preparation.

The Mifepristone standard stock solution was prepared by properly weighing 5 mg of medication and transferring it to a 50-ml flask with a modest amount of mobile phase. i.e., Acetonitrile: Water (70:30, v/v) to dissolve the drug was then sonicated for 10 minutes and the remaining mobile phase was added to make the final volume up to 50 ml to obtain a stock solution containing 100 ppm of Mifepristone.

3.1.2 Sample solution preparation

To prepare the sample solution, weigh 5 mg of equivalent Mifepristone tablet powder into a 50 ml flask and add a tiny amount of mobile phase into the volumetric flask. (Acetonitrile: Water (70:30), v/v), it was then sonicated for about 10 minutes and the remaining mobile phase was added to make the final volume up to 50 ml to obtain a stock solution containing 100 ppm of Mifepristone.

3.2 Chart 1. Chromatographic Conditions

| Criteria          | Condition used                  |
|-------------------|---------------------------------|
| Stationary Phase  | Kromasil C-18 (250 mm × 4.6 mm, 5µm) |
| Mobile Phase      | Acetonitrile: Water (70:30, v/v). |
| Flow              | 1 ml/min                        |
| Detection         | 305 nm                          |
| Run time          | 10 minute                       |

3.3 Method Validation

Specificity, method suitability, precision, LOD, LOQ, linearity, accuracy, and robustness were used to validate the optimised method according to ICH guidelines.

3.4 Specificity

Specificity was evaluated by analysing the standard (100 ppm) and test (100 ppm) and comparing the spectra, and the presence of interference was checked.

3.5 Limit of Detection (LOD) & Limit of Quantification

The limit of detection and the limit of quantification Mifepristone for the proposed method were estimated using the standard deviation method. A calibration curve was prepared in the detection and quantitation range (1-6 ppm).

\[ LOD = 3.3 \times \sigma / S \]
\[ LOQ = 10 \times \sigma / S \]

S = Slope of the Calibration curve.
\( \sigma \) = Std deviation of y-intercepts of calibration line.

3.6 Range and Linearity

By injecting 6 different concentrations of standard Mifepristone solutions in the range of 1-6 ppm, the linearity of the new technique was determined. Six solutions of different
concentrations were prepared from a 100 ppm standard stock solution by pipetting out 0.1, 0.2, 0.3, 0.4, 0.5, and 0.6 ml of stock solution were added to a 10 ml volumetric flask, with the remaining volume made up with mobile phase. The resulting solutions were injected in triplicates into HPLC under optimised chromatographic conditions and the area was measured. An average area for each concentration was calculated. A calibration curve was plotted and interpreted, and $R^2$ was determined.

3.7 Accuracy

The percentage recovery was used to assess the accuracy of the developed approach. Percentage Recovery was calculated at three levels (50%, 100%, and 150%) at three different concentrations of solutions (i.e. 1.5 ppm, 3 ppm, and 4.5 ppm) in triplicates to evaluate the accuracy. 3 different concentrations (i.e. 1.5 ppm, 3 ppm, and 4.5 ppm) were prepared from 100 ppm of standard stock solution and one concentration (i.e. 1 ppm) from 100 ppm of sample solution. The resulting solutions were injected in triplicates to HPLC under optimised chromatographic conditions. A known amount of sample solution (1 ppm) was spiked into three different concentrations of standard solutions (i.e., 1.5 ppm, 3 ppm, and 4.5 ppm). These solutions were injected in triplicates into the HPLC for analysis. Percentage recovery at each level was calculated using a formula:

$$% \text{ Recovery} = \frac{\text{Measured Value}}{\text{True value}} \times 100$$

3.8 Precision

The intraday and inter-day precision of the devised approach were investigated. Sample solutions of Mifepristone in three concentration ranges (i.e., 1.5 ppm, 3 ppm, and 4.5 ppm) were prepared and injected in triplicates into HPLC for analysis. At each concentration level, the peak area was measured and the percent RSD was calculated. Similarly, the intraday and inter-day precision studies were done.

Intraday precision: In intraday precision, analysis was conducted twice at various times on the same day.

Interday precision: In interday precision, analysis was conducted for two consecutive days.

3.9 Robustness

The method's robustness was assessed by fluctuating method parameters such as change wavelength (303nm, 307nm), flow rate change (0.9 ml/min, 1 ml/min), and mobile phase change composition to (Acetonitrile: Water) (69:31) and (71:29). The robustness was assessed by analysing standard solutions of 3ppm (n= 6) and sample solutions of 3ppm (n= 2) of Mifepristone, and the% RSD was determined.

4. ANALYSIS OF MIFEPRISTONE TABLETS

To analyse the tablet mixture, 5 mg of Mifepristone tablet powder was carefully weighed in a 50-ml volumetric flask, the mobile phase was added, and the flask was sonicated for 15 minutes. The mobile phase was used to dilute the solutions to a volume of 50 ml, shake the solution, and filter to obtain the stock solution containing 100 ppm of Mifepristone. The solution was runned in HPLC in triplicate. The% w/w of Mifepristone in each tablet was calculated using the formula:

$$\% \text{ w/w} = \frac{\text{Area of sample} \times \text{Weight of standard} \times \text{Dilution factor of sample} \times \text{Weight of sample}}{\text{Area of standard} \times \text{Weight of standard} \times \text{Dilution factor of standard} \times \text{Purity of std}}$$

5 RESULTS AND DISCUSSIONS

5.1 Method Development

During method development, various mobile phases were tried at different flow rates and their effects on retention time, capacity factor, area, peak symmetry, and numbers of theoretical plates were evaluated in HPLC to get the optimum resolution. To assess the amount of Mifepristone, a simple, specific, selective, and accurate reverse phase HPLC technique was designed and validated according to ICH guidelines in this work. Acetonitrile and water in different quantities were tested, and a ratio of Acetonitrile: Water (70:30) was carefully chosen as a suitable combination which gave accepted resolution and system suitability. The chromatogram of the developed method of standard Mifepristone is shown in Fig. 3.
5.2 Specificity

It was found that there was no interference in tablets from the mobile phase and excipient. The chromatogram of the blank solution, sample solution, and standard solution is shown in Figs. 4, 5, 6.

5.3 System Suitability Test

The number of theoretical plates was found to be more than 100,000. The tailing factor was less than 2.0. Hence, the developed method is suitable for estimation of Mifepristone as shown in Tables 1 and 2.

5.4 LOD and LOQ

The suggested method's LOD and LOQ were found to be 0.7238 and 0.9562, respectively, at concentrations ranging from 1-6 ppm, as shown in Table 3. The developed method is sensitive enough to detect and quantify the drug at a ppm level.

5.5 Linearity

The method was linear over concentration, ranging between 1-6 ppm, as shown in Table 4. The $R^2$ was 0.9923 and the regression equation $Y = 32780x + 2571.8$. The $R^2$ was greater than 0.99, so the method was stated to be linear and is shown in Fig. 7.

5.6 Accuracy

The result of the established method was discovered to be accurate, as the result of the percent recovery was within the range. The percentage recovery was found to be between 99.39% - 100.50% as shown in Table 5 and 6.

5.7 Precision

The result was demonstrated by intraday and intraday precision at three concentration levels: 1.5 ppm, 3 ppm, and 4.5 ppm. The values of% RSD obtained at each level of both intraday and intraday precision were less than 2, as shown in Tables 7, 8, and 9, 10. As a result, the proposed approach was discovered to be precise.

5.8 Robustness

The method was stated to be robust as the result of% RSD was less than 2. The% w/w was found between 98% and 102% for both unaltered conditions as shown in Table 11 and altered conditions as shown in Tables 12, 13, 14.

Mifepristone is currently used as a contraceptive. From a literature review, it was found that there is no reported Revere Phase HPLC method for estimation of Mifepristone. This research work describes the development and validation of an analytical method for the analysis of Mifepristone. Kromasil C18 column of dimensions 250mm×4.6mm particle size 5 µm and Acetonitrile: Water(70:30, v/v) as the mobile phase at wavelength 305nm. Following the ICH guidelines, the devised approach was validated. With a concentration range of 1-6 ppm and a regression coefficient ($R^2$) of 0.9923, the desired approach was found to be linear. The method for determination of Mifepristone using HPLC met the acceptance criteria with respect to selectivity, system suitability, precision, accuracy, linearity, and robustness over a theoretical concentration range of 1-6 ppm. Mifepristone analysis could be performed using the designed and validated method.
Fig. 4. Blank Chromatogram

Fig. 5. Standard chromatogram

Fig. 6. Chromatogram of test.
Table 1. Mifepristone standard solution system suitability results

| tR   | Area    | NTP  | Height  | Symmetric factor | %RSD |
|------|---------|------|---------|------------------|------|
| 6.27 | 2446023 | 5114 | 123999  | 1.400            |      |
| 6.277| 2421958 | 4985 | 119117  | 1.428            |      |
| 6.279| 2448511 | 5144 | 124869  | 1.403            |      |
| 6.280| 2454430 | 5046 | 122274  | 1.418            |      |
| 6.277| 2441044 | 5253 | 127562  | 1.424            |      |

Table 2. Results of system suitability for sample solution of Mifepristone

| tR   | Area    | NTP  | Height  | Symmetric factor | %RSD |
|------|---------|------|---------|------------------|------|
| 6.277| 2617420 | 9542 | 238574  | 1.157            |      |
| 6.277| 2592888 | 11295| 267178  | 1.065            |      |

Table 3. Results of LOD and LOQ

| Sr. No. | Parameters                                      | Results            |
|---------|-------------------------------------------------|--------------------|
| 1.      | Calibration curve for detection and quantification range | 1-6 ppm            |
| 2.      | Y-Intercept                                      | 2571.8             |
| 3.      | Slope                                           | 32780              |
| 4.      | LOD                                             | 0.2589             |
| 5.      | LOQ                                             | 0.7845             |

![Calibration curve of mifepristone](image)

Table 4. Results of linearity study for mifepristone

| Conc. (ppm) | Area 1   | Area2  | Area3  | Average area |
|-------------|----------|--------|--------|--------------|
| 1           | 33017    | 30253  | 27861  | 30377        |
| 2           | 69709    | 65930  | 57717  | 64452        |
| 3           | 100184   | 90565  | 99890  | 96879        |
| 4           | 12832    | 128288 | 128422 | 128346       |
| 5           | 15242    | 153924 | 148718 | 151689       |
| 6           | 200198   | 203318 | 200082 | 201199       |

Regression equation: $Y = 32780x + 2571.8$

$R^2 = 0.9923$
Table 5. Results of accuracy of developed HPLC method at three different levels (50%, 100%, 150%)

| Levels | Conc. (ppm) | Replicate | Area   |
|--------|-------------|-----------|--------|
| (Test) 0 | 1           | 1         | 27144  |
|         | 2           |           | 22039  |
|         | 3           |           | 22439  |
| (Std) 50 | 1.5         | 1         | 43851  |
|         | 2           |           | 46340  |
|         | 3           |           | 45694  |
| (Std) 100 | 3           | 1         | 74426  |
|         | 2           |           | 75760  |
|         | 3           |           | 75383  |
| (Std) 150 | 4.5         | 1         | 104831 |
|         | 2           |           | 106036 |
|         | 3           |           | 106598 |
| (spike) 50 | 1.5+1      | 1         | 71412  |
|         | 2           |           | 68535  |
|         | 3           |           | 68037  |
| (spike) 100 | 3+1        | 1         | 101240 |
|         | 2           |           | 97769  |
|         | 3           |           | 99405  |
| (spike) 150 | 4.5+1      | 1         | 129932 |
|         | 2           |           | 127887 |
|         | 3           |           | 129367 |

Table 6. Results of % recovery of mifepristone by developed HPLC method

| % Levels | Replicate | % Recovery | Mean% recovery ±SD | % RSD |
|----------|-----------|------------|--------------------|-------|
| 50%      | 1         | 100.95     | 100.35% ± 0.5853   | 0.5832|
|          | 2         | 100.33     |                    |       |
|          | 3         | 99.78      |                    |       |
| 100%     | 1         | 99.55      | 100.50% ± 0.2084   | 0.2089|
|          | 2         | 99.96      |                    |       |
|          | 3         | 99.82      |                    |       |
| 150%     | 1         | 98.02      | 99.39% ± 1.185     | 1.1922|
|          | 2         | 99.82      |                    |       |
|          | 3         | 100.30     |                    |       |

Table 7. Shows the results of the developed HPLC method’s intraday precision

| Conc. (ppm) | Area 1 | Area 2 | Area 3 | Mean    | % RSD |
|-------------|--------|--------|--------|---------|-------|
| 1.5         | 39200  | 39268  | 39194  | 39220.6 | 0.1   |
| 3           | 72962  | 72859  | 71346  | 72389   | 1.25  |
| 4.5         | 112515 | 112288 | 113994 | 112932.3| 0.82  |

Table 8. Result of intraday precision of developed HPLC method

| Conc. (ppm) | Area 1 | Area 2 | Area 3 | Mean    | % RSD |
|-------------|--------|--------|--------|---------|-------|
| 1.5         | 36055  | 36977  | 36531  | 36521   | 1.26  |
| 3           | 66861  | 67539  | 67050  | 67150   | 0.52  |
| 4.5         | 110650 | 112449 | 111663 | 111587.3| 0.8   |
Table 9. Result of interday precision of developed HPLC method

| Conc. (ppm) | Area 1   | Area 2   | Area 3   | Mean         | % RSD  |
|-------------|----------|----------|----------|--------------|--------|
| 1.5         | 36025    | 35764    | 36036    | 35941.67     | 0.4283 |
| 3           | 70227    | 71012    | 69331    | 70190        | 1.1983 |
| 4.5         | 112470   | 114682   | 111733   | 112961.7     | 1.3586 |

Table 10. Result of interday precision of developed HPLC method

| Conc. (ppm) | Area 1   | Area 2   | Area 3   | Mean         | % RSD  |
|-------------|----------|----------|----------|--------------|--------|
| 1.5         | 35079    | 34987    | 35631    | 35232.33     | 0.9885 |
| 3           | 67849    | 66643    | 67619    | 67370.33     | 0.9504 |
| 4.5         | 112599   | 113459   | 114371   | 113476.3     | 0.7808 |

Table 11. Results of robustness study (unaltered)

| Conc. (ppm) | Area | t_R  | Std |
|-------------|------|------|-----|
| Std 3 ppm   | 6.367| 64813|
|             | 6.347| 66123|
|             | 6.357| 65727|
| Test 3 ppm  | 6.357| 64892|
|             | 6.353| 63196|
|             | 6.360| 66022|
|             | 6.370| 65005|
|             | 6.373| 65577|

SD = 944.0522
Mean = 65169.38
% RSD = 1.44

Table 12. Results of effect of change in flow rate on proposed HPLC method for mifepristone

| Flow rate of 0.9 ml/min | | | Flow rate of 1.1 ml/min | | |
|-------------------------|----------------|---------------------|-------------------------|----------------|----------------|
| Conc. (ppm)             | t_R  | Area    | Conc. (ppm)             | t_R  | Area    |
| Std 3 ppm               | 7.090| 69477   | Std 3 ppm               | 6.383| 62422   |
|                         | 7.097| 70574   |                         | 6.377| 61904   |
|                         | 7.097| 70038   |                         | 6.377| 61433   |
|                         | 7.097| 70737   |                         | 6.383| 61817   |
|                         | 7.097| 69047   |                         | 6.323| 61820   |
|                         | 7.093| 70830   |                         | 6.387| 62320   |
| Test 3 ppm             | 7.093| 75236   | Test 3 ppm              | 6.420| 64359   |
|                         | 7.093| 76550   |                         | 6.380| 63897   |

SD = 635.3607
Mean = 70186.13
% RSD = 0.9053

SD = 1060.22
Mean = 62496.5
% RSD = 1.69

Table 13. Results of effect of change in wavelength on proposed HPLC method for mifepristone

| 303 nm | | | 307 nm | | |
|--------|----------------|-------------|---------|----------------|-------------|
| Conc. (ppm) | t_R  | Area    | Conc. (ppm) | t_R  | Area    |
| Std 3 ppm   | 6.367| 64514   | Std 3 ppm   | 6.367| 65464   |
|             | 6.347| 67514   |             | 6.350| 65478   |
|             | 6.357| 66763   |             | 6.357| 65470   |
|             | 6.357| 65642   |             | 6.357| 63816   |
### Table 14. Result of analysis of tablet by HPLC

| Drug           | Conc. (ppm) | Area    | % RSD  | % Assay |
|----------------|-------------|---------|--------|---------|
| Mifepristone   | 100         | 2617420 | 1.4582 | 102%    |
|                |             | 2592888 |        |         |
|                |             | 2632670 |        |         |

### 6. CONCLUSIONS

In accordance with ICH guidelines, all validity parameters for the methods developed were studied. All limits have been shown to be exact, specific, targeted, reliable, and reproductive. The procedure should also be used in pure and pharmaceutical dosing for the regular study of mifepristone.

### DISCLAIMER

The products used for this research are commonly and predominantly used products in our area of research and country. There is absolutely no conflict of interest between the authors and producers of the products because we do not intend to use these products as an avenue for any litigation but for the advancement of knowledge. Also, the research was not funded by the producing company rather it was funded by personal efforts of the authors.

### CONSENT

As per international standard or university standard, patients’ written consent has been collected and preserved by the author(s).

### ETHICAL APPROVAL

It is not applicable.

### ACKNOWLEDGEMENT

The authors are grateful from Fisher Scientific India Pvt. Ltd for provide free gift sample for research.

### COMPETING INTERESTS

Authors have declared that no competing interests exist.

### REFERENCES

1. Klima CS. Unintended pregnancy: Consequences and solutions for a worldwide problem. Journal of Nurse-Midwifery. 1998;43(6):483-91.
2. Yazdkhasti M, Pourreza A, Pirak A, Abdi F. Unintended pregnancy and its adverse social and economic consequences on health system: An narrative review article. Iranian Journal of Public Health. 2015;44(1):12-18.
3. Singh S, Shekhar C, Acharya R, Moore AM, Stillman M, Pradhan MR, Frost JJ, Sahoo H, Alagarajan M, Hussain R, Sundaram A. The incidence of abortion and unintended pregnancy in India, 2015. The Lancet Global Health. 2018;6(1):111-20.
4. Jain R, Muralidhar S. Contraceptive methods: Needs, options and utilization. The Journal of Obstetrics and Gynaecology of India. 2011;61(6):626-34.
5. Norman JE, Kelly RW, Baird DT. Uterine activity and decidual prostaglandin production in women in early pregnancy in response to mifepristone with or without indomethacin in-vivo. Human Reproduction. 1991;6(5):740-4.
6. Johanssen S, Alloio B. Mifepristone (RU 486) in Cushing’s syndrome. European Journal of Endocrinology. 2007;157(5):561-70.
7. Bidyasagar M, Ravikumar K, Rama RA, Reddy MM, Singh AK. Structural studies of intermediates in the synthesis of mifepristone (RU486). I. An 11β-substituted steroid. Acta Crystallographica Section C: Crystal Structure Communications. 1994;50(12):2089-2093.

8. Bokström H, Norström A. Effects of mifepristone and progesterone on collagen synthesis in the uterine cervix. Contraception. 1995;51(4):249-54.

9. Li CL, Chen DJ, Song LP, Wang Y, Zhang ZF, Liu MX, Chen WL. Effectiveness and safety of lower doses of mifepristone combined with misoprostol for the termination of ultra-early pregnancy: a dose-ranging randomized controlled trial. Reproductive sciences. 2015;22(6):706-11.

10. Homer NZ, Reynolds RM, Mattsson C, Bailey MA, Walker BR, Andrew R. Quantitative analysis of RU38486 (mifepristone) by HPLC triple quadrupole mass spectrometry. Journal of Chromatography B. 2009;877(5-6):497-501.

11. Stith C, Hussain MD. Determination of mifepristone levels in wild can serum using liquid chromatography. Journal of Chromatography B. 2003;794(1):9-15.

12. Guo Z, Chu C, Yin G, He M, Fu K, Wu J. An HPLC method for the determination of mifepristone in human plasma. Journal of Chromatography B. 2006;832(2):181-184.

13. Guo Z, Wang S, Wei D, Zhai J. Development of a high-performance liquid chromatographic method for the determination of mifepristone in human plasma using nor-ethisterone as an internal standard: application to pharmacokinetic study. Contraception. 2007;76(3):228-32.

14. Guo Z, Wei D, Yin G, Wang S, Zhao S, Chu Y, Zhai J. Simultaneous determination of rivanol and mifepristone in human plasma by a HPLC-UV method with solid-phase extraction. Journal of Chromatography B. 2007;856(1-2):312-317.

15. Ishii A, Zaitsu K, Kusano M, Asano T, Ogawa T, Hattori H, Seno H. Identification and quantitation of mifepristone and its N-demethyl metabolite in the plasma of an aborted fetus by liquid chromatography–quadrupole–time-of-flight–mass spectrometry (LC–Q–TOFMS) and ultra-performance liquid chromatography and mass spectrometry (UPLC MS). Forensic Toxicology. 2015;33(2):409-12.

16. Kadioglu Y, Albavrak M, Demirkaya F. Development and validation of RP-HPLC-DAD method for determination of progesterone in capsule. Reviews in Analytical Chemistry. 2010;29 (3-4):197-210.

© 2021 Bastia et al.; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peer-review history:
The peer review history for this paper can be accessed here: https://www.sdiarticle5.com/review-history/79719